Thermo Fisher Scientific (TMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2012 | 03-2012 | 12-2011 | 09-2011 | 06-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 732,300 | 788,300 | 1,016,300 | 890,300 | 1,356,100 |
| Marketable Securities | 4,300 | 4,300 | 4,300 | 8,000 | 7,600 |
| Receivables | 1,803,500 | 1,894,800 | 1,763,700 | 1,811,000 | 1,683,400 |
| Inventories | 1,390,700 | 1,422,300 | 1,330,100 | 1,406,100 | 1,350,400 |
| Income taxes - deferred | 177,900 | 160,100 | 157,800 | 204,100 | 195,200 |
| Other current assets | 558,300 | 499,700 | 549,700 | 415,100 | 412,000 |
| TOTAL | $4,667,000 | $4,769,500 | $4,821,900 | $4,734,600 | $5,004,700 |
| Non-Current Assets | |||||
| PPE Net | 1,602,500 | 1,665,300 | 1,611,300 | 1,629,200 | 1,509,500 |
| Intangibles | 19,546,300 | 19,823,600 | 19,789,200 | 20,062,400 | 17,023,400 |
| Other Non-Current Assets | 545,500 | 564,300 | 611,300 | 565,300 | 536,200 |
| TOTAL | $21,694,300 | $22,053,200 | $22,011,800 | $22,256,900 | $19,069,100 |
| Total Assets | $26,361,300 | $26,822,700 | $26,833,700 | $26,991,500 | $24,073,800 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 652,600 | 691,400 | 612,300 | 610,600 | 632,900 |
| Accrued Expenses | 299,900 | 301,800 | 324,400 | 326,800 | 262,800 |
| TOTAL | $2,703,200 | $2,845,400 | $3,113,100 | $2,792,500 | $1,816,800 |
| Non-Current Liabilities | |||||
| Long Term Debt | 5,745,900 | 5,751,000 | 5,755,200 | 6,115,300 | 4,008,800 |
| Deferred Revenues | 215,300 | 227,400 | 192,500 | 192,600 | 205,000 |
| Other Non-Current Liabilities | 709,700 | 718,600 | 698,000 | 625,400 | 625,700 |
| TOTAL | $8,563,700 | $8,688,300 | $8,682,500 | $9,003,100 | $6,591,300 |
| Total Liabilities | $11,266,900 | $11,533,700 | $11,795,600 | $11,795,600 | $8,408,100 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 365,552 | 367,303 | 365,854 | 378,280 | 381,873 |
| Common Shares | 408,700 | 408,500 | 406,400 | 406,300 | 405,900 |
| Retained earnings | 7,131,600 | 6,945,600 | 6,716,300 | 6,427,400 | 6,162,000 |
| Other shareholders' equity | -457,900 | -150,900 | -399,600 | -279,300 | 266,200 |
| TOTAL | $15,094,400 | $15,289,000 | $15,038,100 | $15,195,900 | $15,665,700 |
| Total Liabilities And Equity | $26,361,300 | $26,822,700 | $26,833,700 | $26,991,500 | $24,073,800 |